Stroke Prevention Breakthrough: Medtronic Launches Full Distribution of 3-in-1 Carotid Stent with 40-Micron Embolic Protection Filter

A Device Rewrites the Landscape of Carotid Artery Surgery

10 Month 10 Date, global medical giant Medtronic officially announced full distribution FDA Approved Neuroguard IEP System —— This product integrates stent, dilation balloon, and embolic protection filter. “Three-in-One” Carotid Artery Stents Are Quietly Reshaping the Clinical Rules of Stroke Prevention. For those suffering from carotid artery disease each year, 80 In the U.S. market of tens of thousands of stroke cases, this innovation is remarkable “Timely Rain”。

I.40 The Life-and-Death Race of Micron Filters: Stopping Fatal Emboli Missed by Traditional Devices

The most perilous risk during carotid artery stenting is the stroke caused by dislodged microemboli during the procedure.Contego Medical Founder Ravish Sachar Dr. stated directly:“Traditional protective devices always have loopholes, and Neuroguard The 40 Micron integrated filter, capable of capturing tiny particles that other devices cannot intercept.”

How astonishing is this precision? Comparison 2021 Approved in Asia in [Year] TriGUARD3 Device 145×115μm The filter mesh aperture,Neuroguard The capture capability has improved nearly 3 Times.PERFORMANCE II The study also provides hardcore data: even if 34.5% Patients with severe calcification in the lesion post-operation 30 Day to 1 The incidence of serious complications such as major strokes and stent thrombosis within the year remains at zero.

2. Loosening of Medical Insurance Restrictions + Technological Innovation: The Volume of Carotid Artery Surgeries to Experience Explosive Growth

The launch of this device coincides with the industry upswing.2023 Year 10 Monthly U.S. Medicare NCD After the policy adjustment, the reimbursement scope for carotid artery stents has significantly expanded, and experts predict a notable increase in the number of surgeries. Neuroguard The “Three-in-One” Design directly addresses clinical pain points —— In the past, stents, balloons, and filters had to be placed in multiple stages, but now they can be completed in a single procedure, not only shortening operation time but also reducing operational risks.

President of Medtronic Peripheral Vascular Health David Moeller Emphasize:“This is not a simple product overlay, but the establishment of a new standard of care for carotid artery disease.” By contrast, Medtronic currently Protégé RX Although the stent can adapt to different vascular anatomical structures, it requires additional protective devices, making the procedural complexity much higher than that of the newer model.

III. From Equity Investment to Full Distribution: Medtronic's Ambition in the Carotid Artery Market

This full-scale distribution is no accident. Medtronic, since 2020 Held since Contego Minority equity,2025 Year 1 Further signed an exclusive distribution agreement in the month and obtained an acquisition option, with a clear strategic layout:

1.Fill Technological Gaps:Protégé RX Mainly featuring traditional self-expanding stents,Neuroguard Then seize the integrated protection device track;

2.Betting on Policy Benefits: After the Expansion of Medical Insurance Reimbursement, the Demand for Simplified Equipment in Grassroots Medical Institutions Surges;

3.Lock in Future Innovation:Contego In progress PERFORMANCE III Test, Evaluate the Next Generation TCAR-IEP The system, if successful, will further simplify the surgical process.

4. Enlightenment for the Chinese Market: The Localization of Peripheral Intervention Devices in China Awaits a Breakthrough

Although this release focuses on the U.S. market, its reference significance for China is substantial. Data shows that the annual number of carotid artery stenosis surgeries in China exceeds... 15 Ten thousand units, but no domestically produced stents have been approved yet, relying on imported older models for a long time. With the implementation of centralized peripheral intervention procurement, the number of surgeries is expected to increase. 30%, the market demand for innovative devices is already at a critical point. Medtronic's “Technology + Channel” Approach, perhaps precisely the breakthrough direction for domestically produced enterprises.

When 40 Micron filter nets block fatal emboli, while the three-in-one design simplifies the surgical process.Neuroguard The emergence is not only an innovation in equipment, but also a “Stroke is Preventable” Clinical commitment. With PERFORMANCE III Test Progress, Can the Next Generation of Devices Be Achieved “Less Invasive, Safer” The goal? We will wait and see.